{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:31:37Z","timestamp":1784302297154,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The association between chronic inflammatory conditions and cardiovascular disease is well established. Considering FMF, few studies exist investigating the risk of ischaemic heart disease, and none address the risk of stroke. We aimed to evaluate the incidence and risk for stroke in FMF patients compared with the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study using the electronic database of Clalit Health Services (CHS), the largest health organization in Israel. All FMF patients diagnosed between 2000 and 2016 were included and matched with control according to age, gender and place of residence. Follow-up continued until the first diagnosis of stroke or death. The incidence of stroke was compared between the groups using univariate and multivariate models adjusting for cardiovascular risk-factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 9769 FMF patients and a similar number of controls were followed up for a median period of 12.5\u2009years. The mean age at the beginning of the follow-up was 25.7\u2009years. In total, 208 FMF patients were diagnosed with stroke compared with 148 controls, resulting in an incidence rate (per 10\u2009000 persons-years) of 19.8 (95% CI 17.2, 22.7) and 13.9 (95% CI 11.8, 16.4), respectively, and a crude HR of 1.42 (95% CI 1.15\u20131.76; P\u2009&amp;lt;\u20090.001). In a multivariate analysis, FMF patients who developed amyloidosis with related or non-related renal failure demonstrated significant stroke risk (HR\u2009=\u20092.16; 95% CI 1.38, 3.38; P\u2009&amp;lt;\u20090.001), as well as for those who did not develop these complications (HR\u2009=\u20091.32; 95% CI 1.04, 1.67; P\u2009&amp;lt;\u20090.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>FMF patients are at increased risk for stroke regardless of known complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead153","type":"journal-article","created":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T13:10:30Z","timestamp":1680441030000},"page":"3940-3946","source":"Crossref","is-referenced-by-count":10,"title":["Increased risk for stroke in patients with familial Mediterranean fever: results from a large population-based study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-2003","authenticated-orcid":false,"given":"Niv","family":"Ben-Shabat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Gendelman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uria","family":"Shani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-1729","authenticated-orcid":false,"given":"Yonatan Shneor","family":"Patt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-8027","authenticated-orcid":false,"given":"Abdulla","family":"Watad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Skuja","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Riga Stradins University , Riga, Latvia"},{"name":"Anti-Aging Institute, Health Center 4 , Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"},{"name":"NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton, Leeds Teaching Hospital Trust , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-7716","authenticated-orcid":false,"given":"Howard","family":"Amital","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine B, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center , Tel-Hashomer, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,2]]},"reference":[{"key":"2023120200581282800_kead153-B1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10067-017-3715-5","article-title":"Familial Mediterranean fever, review of the literature","volume":"36","author":"Alghamdi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2023120200581282800_kead153-B2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/annrheumdis-2012-202932","article-title":"Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents","volume":"73","author":"Twig","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrrheum.2010.181","article-title":"Chronic inflammation in FMF: markers, risk factors, outcomes and therapy","volume":"7","author":"Ben-Zvi","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2023120200581282800_kead153-B4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"2023120200581282800_kead153-B5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis"},{"key":"2023120200581282800_kead153-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jdv.12742","article-title":"Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink","volume":"29","author":"Edson-Heredia","year":"2015","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"2023120200581282800_kead153-B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/1570161118666200129125320","article-title":"Primary Sj\u00f6gren\u2019s syndrome and cardiovascular disease","volume":"18","author":"Melissaropoulos","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"2023120200581282800_kead153-B8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"Schoenfeld","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2023120200581282800_kead153-B9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ Br Med J"},{"key":"2023120200581282800_kead153-B12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"252","author":"Piepoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"2023120200581282800_kead153-B13","first-page":"1","article-title":"Intima media thickness of carotid arteries in familial Mediterranean fever: a systematic review and meta-analysis","volume":"3","author":"Merashli","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2023120200581282800_kead153-B14","first-page":"9","article-title":"Prevalence of ischemic heart disease in patients with familial Mediterranean fever","volume":"3","author":"Langevitz","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"2023120200581282800_kead153-B15","doi-asserted-by":"crossref","first-page":"e13473","DOI":"10.1111\/ijcp.13473","article-title":"Familial Mediterranean fever is associated with increased risk for ischaemic heart disease and mortality-perspective derived from a large database","volume":"74","author":"Gendelman","year":"2020","journal-title":"Int J Clin Pract"},{"key":"2023120200581282800_kead153-B16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Abbafati","year":"2020","journal-title":"Lancet"},{"key":"2023120200581282800_kead153-B17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B18","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1093\/eurheartj\/ehac516","article-title":"Association of anti-Ro seropositivity with cardiac rhythm and conduction disturbances","volume":"43","author":"Akuka","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120200581282800_kead153-B19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"2023120200581282800_kead153-B20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/09612033211004726","article-title":"The coexistence of familial Mediterranean fever (FMF) in systemic lupus erythematosus (SLE) patients - a cross sectional study","volume":"30","author":"Klein","year":"2021","journal-title":"Lupus"},{"key":"2023120200581282800_kead153-B21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jad.2021.05.113","article-title":"The risk of depression and anxiety in patients with familial Mediterranean fever - a cross-sectional study","volume":"292","author":"Lidor","year":"2021","journal-title":"J Affect Disord"},{"key":"2023120200581282800_kead153-B22","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1093\/rheumatology\/keab159","article-title":"Familial Mediterranean fever and asthma","volume":"60","author":"Tsur","year":"2021","journal-title":"Rheumatology"},{"key":"2023120200581282800_kead153-B23","first-page":"404","article-title":"Prevalence of selected chronic diseases in Israel","volume":"3","author":"Rennert","year":"2001","journal-title":"IMAJ"},{"key":"2023120200581282800_kead153-B24","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","article-title":"Anti\u2013tumor necrosis factor-\u03b1 treatment improves endothelial function in patients with rheumatoid arthritis","volume":"106","author":"H\u00fcrlimann","year":"2002","journal-title":"Circulation"},{"key":"2023120200581282800_kead153-B25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023120200581282800_kead153-B26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023120200581282800_kead153-B28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/rheumatology\/kep131","article-title":"Intima-media thickening in patients with familial Mediterranean fever","volume":"48","author":"Ugurlu","year":"2009","journal-title":"Rheumatology"},{"key":"2023120200581282800_kead153-B29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s10067-006-0529-2","article-title":"Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever","volume":"26","author":"Sari","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2023120200581282800_kead153-B30","article-title":"Interventions for reducing inflammation in familial Mediterranean fever","volume":"2018","author":"Wu","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023120200581282800_kead153-B31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.11613\/BM.2012.012","article-title":"Relationship between serum interleukin-1beta levels and acute phase response proteins in patients with familial Mediterranean fever","volume":"22","author":"Yildirim","year":"2012","journal-title":"Biochem Medica"},{"key":"2023120200581282800_kead153-B32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5152\/npa.2016.12396","article-title":"Changes in cerebral blood flow in patients with familial Mediterranean fever","volume":"54","author":"\u00c7etin","year":"2017","journal-title":"Noro Psikiyatr Ars"},{"key":"2023120200581282800_kead153-B33","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.jacc.2006.09.013","article-title":"Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF","volume":"48","author":"Akdogan","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2023120200581282800_kead153-B34","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00296-008-0605-9","article-title":"Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis","volume":"28","author":"Bilginer","year":"2008","journal-title":"Rheumatol Int"},{"key":"2023120200581282800_kead153-B35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/gene.2011.53","article-title":"The regulation of MEFV expression and its role in health and familial Mediterranean fever","volume":"12","author":"Grandemange","year":"2011","journal-title":"Genes Immun"},{"key":"2023120200581282800_kead153-B36","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.cdd.4402142","article-title":"The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1\u03b2 processing","volume":"14","author":"Papin","year":"2007","journal-title":"Cell Death Differ"},{"key":"2023120200581282800_kead153-B37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1744-313X.2010.00938.x","article-title":"The rate of MEFV gene mutations in hematolymphoid neoplasms","volume":"37","author":"Celik","year":"2010","journal-title":"Int J Immunogenet"},{"key":"2023120200581282800_kead153-B38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023120200581282800_kead153-B39","doi-asserted-by":"crossref","first-page":"103532","DOI":"10.1016\/j.ejmg.2018.08.013","article-title":"Familial Mediterranean fever (FMF) phenotype in patients homozygous to the MEFV M694V mutation","volume":"62","author":"Grossman","year":"2019","journal-title":"Eur J Med Genet"},{"key":"2023120200581282800_kead153-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.md.0000152370.84628.0c","article-title":"Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study","volume":"84","author":"Tunca","year":"2005","journal-title":"Medicine"},{"key":"2023120200581282800_kead153-B41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/rheumatology\/39.1.67","article-title":"Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis","volume":"39","author":"Yal\u00e7inkaya","year":"2000","journal-title":"Rheumatology"},{"key":"2023120200581282800_kead153-B42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.gene.2011.10.012","article-title":"Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients","volume":"492","author":"Akpolat","year":"2012","journal-title":"Gene"},{"key":"2023120200581282800_kead153-B43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5152\/eurjrheum.2014.006","article-title":"Familial Mediterranean fever: an updated review","volume":"1","author":"Sar\u0131","year":"2014","journal-title":"Eur J Rheumatol"},{"key":"2023120200581282800_kead153-B44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9343(67)90167-2","article-title":"Familial Mediterranean fever. A survey of 470 cases and review of the literature","volume":"43","author":"Sohar","year":"1967","journal-title":"Am J Med"},{"key":"2023120200581282800_kead153-B45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ahj.2019.09.011","article-title":"The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics","volume":"218","author":"Nidorf","year":"2019","journal-title":"Am Heart J"},{"key":"2023120200581282800_kead153-B46","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur Heart J"},{"key":"2023120200581282800_kead153-B47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-9-3","article-title":"Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study","volume":"9","author":"Ben-Zvi","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"2023120200581282800_kead153-B48","doi-asserted-by":"crossref","first-page":"P81","DOI":"10.1186\/1546-0096-13-S1-P81","article-title":"Compliance to colchicine treatment and disease activity in Familial Mediterranean Fever (FMF) patients in Middle\/Black Sea Region of Turkey (in \u00c7orum region)","volume":"13","author":"Karaaslan","year":"2015","journal-title":"Pediatr Rheumatol"},{"key":"2023120200581282800_kead153-B49","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/art.24570","article-title":"Clinical disease among patients heterozygous for familial Mediterranean fever","volume":"60","author":"Marek-Yagel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023120200581282800_kead153-B50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10067-016-3421-8","article-title":"Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants","volume":"36","author":"S\u00f6nmez","year":"2017","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead153\/49871455\/kead153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/12\/3940\/53972348\/kead153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/12\/3940\/53972348\/kead153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:58:58Z","timestamp":1701478738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/12\/3940\/7099605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,2]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,4,2]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead153","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,4,2]]}}}